Octapharma: Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq in Previously Untreated Patients With Severe Haemophilia A in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal
Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq
) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623).
The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq
. The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 110 patients, the NuProtect study was the largest clinical study to investigate a single